Acquired resistance to proteasome inhibition has been correlated in cellular models with UPP upregulation and/or mutations of the PSMB5 gene; yet, no mutations have been found in the PSMB5 gene in myeloma patients being refractory to or relapsed from BTZ therapy [24, 25]. Here, PSMB5 is linked to plasma cell myeloma.